Since obtaining US Food and Drug Administration approval of Rybrevant in a small subset of non-small cell lung cancer (NSCLC) patients in 2021, Janssen Pharmaceutical Cos. has eyed a much bigger opportunity by seeking data readouts that would position its bispecific antibody to compete with AstraZeneca PLC’s Tagrisso (osimertinib) in EGFR-driven mutations that comprise a larger segment of the NSCLC population.
J&J Lung Cancer Ambitions Possibly Boosted By New Rybrevant Data
New Rybrevant Data Could Boost J&J Lung Cancer Ambitions
Improvements in PFS compared to chemotherapy may help broaden Rybrevant’s indication in EGFR-mutated non-small cell lunger cancer. Investors await data from a head-to-head trial testing it versus AstraZeneca’s Tagrisso.
More from Clinical Trials
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
More from R&D
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.